Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Study Summary

The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Conditions

Cystic Fibrosis

Interventions / Drugs

VX-121/TEZ/D-IVA

View on ClinicalTrials.gov ↗

Sponsor

VRTX

Vertex Pharmaceuticals

Gene Therapy

C55/100

Study Details

Enrollment210 participants

Primary Completion—

Lead SponsorVertex Pharmaceuticals Incorporated

Data Retrieved2026-04-11 02:55:58.035209+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.